Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Possible Fungal Infection
Interventions
DRUG

voriconazole (Vfend)

voriconazole, early treatment

DRUG

voriconazole (Vfend)

voriconazole, deferred treatment

Trial Locations (28)

10117

Pfizer Investigational Site, Berlin

12200

Pfizer Investigational Site, Berlin

13353

Pfizer Investigational Site, Berlin

14467

Pfizer Investigational Site, Potsdam

15236

Pfizer Investigational Site, Frankfurt (Oder)

23538

Pfizer Investigational Site, Lübeck

24116

Pfizer Investigational Site, Kiel

28177

Pfizer Investigational Site, Bremen

30623

Pfizer Investigational Site, Hanover

33611

Pfizer Investigational Site, Bielefeld

37075

Pfizer Investigational Site, Göttingen

45239

Pfizer Investigational Site, Essen

50937

Pfizer Investigational Site, Cologne

54290

Pfizer Investigational Site, Trier

55101

Pfizer Investigational Site, Mainz

65191

Pfizer Investigational Site, Wiesbaden

66421

Pfizer Investigational Site, Homburg/Saar

67063

Pfizer Investigational Site, Ludwigshafen

70376

Pfizer Investigational Site, Stuttgart

79106

Pfizer Investigational Site, Freiburg im Breisgau

81675

Pfizer Investigational Site, München

81737

Pfizer Investigational Site, München

86156

Pfizer Investigational Site, Augsburg

91054

Pfizer Investigational Site, Erlangen

97070

Pfizer Investigational Site, Würzburg

09113

Pfizer Investigational Site, Chemnitz

01307

Pfizer Investigational Site, Dresden

04103

Pfizer Investigational Site, Leipzig

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

UNKNOWN

lead

Pfizer

INDUSTRY